The Blood Glucose-lowering Effect of Racecadotril is not Attributable to Inhibition of Insulin-degrading Enzyme

S. Kurklinsky; S. O. Abdul-Hay; M. P. McGuire; E. A. Howard; J. Knight; M. A. Leissring

doi:10.1055/s-0033-1353211

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2014; 46(01): 73-74
DOI: 10.1055/s-0033-1353211

Letter to the Editor

The Blood Glucose-lowering Effect of Racecadotril is not Attributable to Inhibition of Insulin-degrading Enzyme

S. Kurklinsky^*

¹Department of Neuroscience, Mayo Clinic, Jacksonville, USA

,

S. O. Abdul-Hay^*

¹Department of Neuroscience, Mayo Clinic, Jacksonville, USA

,

M. P. McGuire

¹Department of Neuroscience, Mayo Clinic, Jacksonville, USA

,

E. A. Howard

¹Department of Neuroscience, Mayo Clinic, Jacksonville, USA

,

J. Knight

¹Department of Neuroscience, Mayo Clinic, Jacksonville, USA

,

M. A. Leissring

¹Department of Neuroscience, Mayo Clinic, Jacksonville, USA

› Author Affiliations

Abstract

Full Text

References

References
1 Lee JP, Cheng KC, Chung HH, Wu HT, Chen CT, Cheng JT. Inhibition of insulin degrading enzyme by racecadotril in the brain of wistar rats. Horm Metab Res 2011; 43: 489-493
2 Leissring MA, Malito E, Hedouin S, Reinstatler L, Sahara T, Abdul-Hay SO, Choudhry S, Maharvi GM, Fauq AH, Huzarska M, May PS, Choi S, Logan TP, Turk BE, Cantley LC, Manolopoulou M, Tang W-J, Stein RL, Cuny GD, Selkoe DJ. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One 2010; 5: e10504
3 Neant-Fery M, Garcia-Ordonez RD, Logan TP, Selkoe DJ, Li L, Reinstatler L, Leissring MA. Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proc Natl Acad Sci USA 2008; 105: 9582-9587
4 Cabrol C, Huzarska MA, Dinolfo C, Rodriguez MC, Reinstatler L, Ni J, Yeh L-A, Cuny GD, Stein RL, Selkoe DJ, Leissring MA. Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One 2009; 4: e5274
5 Abdul-Hay SO, Lane AL, Caulfield TR, Claussin C, Bertrand J, Masson A, Choudhry S, Fauq AH, Maharvi GM, Leissring MA. Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate selectivity. J Med Chem 2013; 56: 2246-2255
6 Shii K, Yokono K, Baba S, Roth RA. Purification and characterization of insulin-degrading enzyme from human erythrocytes. Diabetes 1986; 35: 675-683
7 Makarova KS, Grishin NV. The Zn-peptidase superfamily: functional convergence after evolutionary divergence. J Mol Biol 1999; 292: 11-17
8 Shen Y, Joachimiak A, Rosner MR, Tang WJ. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 2006; 443: 870-874
9 Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun C-Y, Meredith SC, Sisodia SS, Leissring MA, Tang W-J. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J Biol Chem 2007; 282: 25453-25463